Identification of minimally invasive biomarkers to monitor chronic disease progression and to assess efficacy and safety of new therapies and vaccines
The major goal of this project is the identification of new biomarkers that can be detected by minimally invasive methods (as drawing of very small volumes of peripheral blood) and that allow to strictly monitor disease progression as well as the efficacy and safety of drugs and vaccines. We will assess the presence in human sera of two types of molecules of interest:
1) Autoantibodies: through an immunoproteomic approach that allows the preparation and exploitation of protein arrays composed by thousands of human proteins for the identification and characterization of serum autoantibodies.
2) MicroRNAs: through the development of a platform for the molecular detection and identification of regulatory RNA (in particular microRNAs) circulating in human serum associated to either protein complexes or vesicles, called exosomes.
Despite the two approaches differ at a methodological and technological level, they have both the goal of responding to the following unmet medical needs:
a) Identify biomarkers in the serum of patients affected by chronic diseases to identify the individuals who will develop the worst complications.
b) Identify biomarkers in the serum of patients and healthy subjects to prognosticate the individuals who will respond better to drugs and vaccines.
c) Assess whether it is possible to diagnose unwanted effects of drugs and vaccines, during clinical trials, before they become clinically evident.
- Identification of autoantibodies as minimally invasive biomarkers to monitor chronic disease progression and improve diagnosis
- Identification of serum microRNAs as minimally invasive biomarkers to monitor chronic disease progression and improve diagnosis
|Nome / Name||Ruolo / Role|
|Mauro Bombaci, PhD||Staff Scientistfirstname.lastname@example.org|
|Susanna Campagnoli||Laboratory Technicianemail@example.com|
|Renata Grifantini, PhD||Group Leaderfirstname.lastname@example.org|
|Paola Gruarin, PhD||Staff Scientistemail@example.com|
|Martina Martinovic||PhD firstname.lastname@example.org|
|Elisa Pesce, PhD||Post Docemail@example.com|
|Maria Lucia Sarnicola||Laboratory Technicianfirstname.lastname@example.org|
|Antonio Enrico Zaurito||Studentemail@example.com|
- Repression of miR-31 by BCL6 stabilizes the helper function of human follicular helper T cells.
Ripamonti A, Provasi E, Lorenzo M, De Simone M, Ranzani V, Vangelisti S, Curti S, Bonnal RJP, Pignataro L, Torretta S, Geginat J, Rossetti G, Pagani M, Abrignani S.
Proc Natl Acad Sci U S A. (2017) 114:12797-12802
- The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance?
Geginat J, Paroni M, Pagani M, Galimberti D, De Francesco R, Scarpini E, Abrignani S.
Trends Immunol (2017) 38:498-512
- Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity.
Torri A, Carpi D, Bulgheroni E, Crosti MC, Moro M, Gruarin P, Rossi RL, Rossetti G, Di Vizio D, Hoxha M, Bollati V, Gagliani C, Tacchetti C, Paroni M, Geginat J, Corti L, Venegoni L, Berti E, Pagani M, Matarese G, Abrignani S, de Candia P.
J Biol Chem (2017) 292:2903-2915
- The circulating microRNome demonstrates distinct lymphocyte subset-dependent signatures.
de Candia P, Torri A, Fedeli M, Vigano V, Carpi D, Gorletta T, Casorati G, Pagani M, Dellabona P, Abrignani S.
Eur J Immunol (2016) 46:725-31
- Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.
De Simone M, Arrigoni A, Rossetti G, Gruarin P, Ranzani V, Politano C, Bonnal RJ, Provasi E, Sarnicola ML, Panzeri I, Moro M, Crosti M, Mazzara S, Vaira V, Bosari S, Palleschi A, Santambrogio L, Bovo G, Zucchini N, Totis M, Gianotti L, Cesana G, Perego RA, Maroni N, Pisani Ceretti A, Opocher E, De Francesco R, Geginat J, Stunnenberg HG, Abrignani S, Pagani M.
Immunity (2016) 45:1135-1147
- Reverse plasticity: TGF-beta and IL-6 induce Th1-to-Th17-cell transdifferentiation in the gut.
Geginat J, Paroni M, Kastirr I, Larghi P, Pagani M, Abrignani S.
Eur J Immunol (2016) 46:2306-2310
- Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets.
Geginat J, Nizzoli G, Paroni M, Maglie S, Larghi P, Pascolo S, Abrignani S.
Front Immunol (2015) 6:527
- The long intergenic noncoding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4.
Ranzani V, Rossetti G, Panzeri I, Arrigoni A, Bonnal RJ, Curti S, Gruarin P, Provasi E, Sugliano E, Marconi M, De Francesco R, Geginat J, Bodega B, Abrignani S, Pagani M.
Nat Immunol (2015) 16:318-325
- Serum microRNAs as Biomarkers of Human Lymphocyte Activation in Health and Disease.
de Candia P, Torri A, Pagani M, Abrignani S.
Front Immunol (2014) 5:43
- Why is it so difficult to develop a hepatitis C virus preventive vaccine?
Zingaretti C, De Francesco R, Abrignani S.
Clin Microbiol Infect (2014) 20 Suppl 5:103-9
- Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b.
Rossi RL, Rossetti G, Wenandy L, Curti S, Ripamonti A, Bonnal RJ, Birolo RS, Moro M, Crosti MC, Gruarin P, Maglie S, Marabita F, Mascheroni D, Parente V, Comelli M, Trabucchi E, De Francesco R, Geginat J, Abrignani S, Pagani M.
Nat Immunol (2011) 12:796-803